Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,891 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,160 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07005297 | Clinical Genetics Branch Eligibility Screening Survey | not yet recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07361484 | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | not yet recruiting | Phase 3 | 442 | BeyondSpring Pharmaceuticals Inc.INDUSTRY | 0 | Sep 29, 2026 |
| clinicaltrials |
| NCT07597070 | Universal Immunization to Fortify Immunotherapy Efficacy and Response(UNIFIER) | not yet recruiting | Phase 2 | 500 | University of FloridaOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLAR-202) | not yet recruiting | Phase 2 | 60 | ExelixisINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07845916 | Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer(QS-NSCLC) | not yet recruiting | Phase 2 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203) | not yet recruiting | Phase 1 / Phase 2 | 84 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07843537 | MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07282444 | A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial(CORRECT) | not yet recruiting | N/A | 194 | Wake Forest University Health SciencesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07663630 | A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss | not yet recruiting | Phase 1 | 80 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07841106 | Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases. | not yet recruiting | Phase 2 | 49 | Jiangmen Central HospitalOTHER | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07842471 | Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC | not yet recruiting | Phase 2 | 117 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07565987 | The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer(APRIL) | not yet recruiting | N/A | 20 | All India Institute of Medical SciencesOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07833202 | A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | not yet recruiting | Phase 3 | 416 | Shanghai Jeyou Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07839325 | MIND-WELL Intervention | not yet recruiting | N/A | 80 | University of ArizonaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07796451 | Low-Frequency rTMS for Sleep After Thoracoscopic Lung Resection(TMS-SLEEP-VATS) | not yet recruiting | N/A | 220 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | not yet recruiting | Phase 4 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07835789 | Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 138 | NRG OncologyOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | not yet recruiting | Phase 2 | 105 | Ming ChenOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07816380 | A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 216 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07833085 | CAIX-targeted PET/CT in Solid Tumors(CAIX-PET) | not yet recruiting | N/A | 100 | Zhongnan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07823725 | TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling(TD-Lung) | not yet recruiting | N/A | 40 | Karolinska InstitutetOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829640 | AI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum | not yet recruiting | N/A | 15 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829744 | Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations | not yet recruiting | Phase 2 | 190 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07830095 | 5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies | not yet recruiting | N/A | 15 | Shanghai Chest HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | not yet recruiting | Phase 3 | 600 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828938 | Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer(QualitySurg) | not yet recruiting | N/A | 2,400 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824544 | An App to Identify Radiation Pneumonitis - a Pre-Study in Healthy Volunteers(POLCAR-HV) | not yet recruiting | N/A | 30 | University Hospital Schleswig-HolsteinOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824882 | A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | not yet recruiting | Phase 2 | 76 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07824986 | A Phase 3 Trial in Advanced Epithelioid Mesothelioma(sTEADfast) | not yet recruiting | Phase 3 | 350 | Vivace Therapeutics, IncINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07806773 | Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 80 | Tubulis GmbHINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822126 | Accurate Planning and Guidance of Bronchoscopy for Lung Cancer Management | not yet recruiting | — | 6 | Penn State UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 448 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07822984 | Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy | not yet recruiting | Phase 2 | 374 | Fudan UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819578 | Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 30 | Shaodong HongOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07819591 | Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC | not yet recruiting | Phase 2 | 47 | Shaodong HongOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07818304 | SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC(Endouble 2) | not yet recruiting | Phase 2 | 61 | The First People's Hospital of LianyungangOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07104253 | Establishing Feasibility of Transbronchial Cryoablation With an In-Development Cryoprobe: An Ex-Vivo Human Lung Model | not yet recruiting | N/A | 10 | Endocision Technologies Inc.INDUSTRY | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07279948 | Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)(LUSIP) | not yet recruiting | — | 477 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment(FATHOM) | not yet recruiting | — | 30,000 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815483 | A Multicenter Cohort Study of AI-Based Methods for Pulmonary Nodule Diagnosis and Follow-up | not yet recruiting | — | 16,880 | Shanghai East HospitalOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials